Hereditary hemochromatosis: pathogenesis, symptoms, diagnosis and current treatment - literature review
DOI:
https://doi.org/10.12775/JEHS.2025.80.58359Keywords
hemochromatosis, iron, hepcidin, phlebotomy, deferoxamine, therapeutic erythrocytapheresisAbstract
Introduction:
Hereditary hemochromatosis is the most common genetic disorder in Northern Europe. It involves an overload of iron in the tissues due to a deficiency of the protein hepcidin. 85-90% of cases are associated with homozygous mutations of the C282Y gene in the HFE gene. Symptoms are nonspecific and include cardiac disorders, liver cirrhosis, hepatocellular carcinoma, diabetes, hypogonadism and sexual dysfunction, and arthritis. The diagnosis of the disease is based on demonstrating elevated serum ferritin levels and transferrin saturation, as well as identifying the mutation responsible for hereditary hemochromatosis. Early diagnosis is crucial in preventing permanent organ complications. Treatment methods include phlebotomy, therapeutic erythrocytophoresis, and the use of iron chelating drugs. Early detected and properly treated hemochromatosis allows for a lifespan comparable to the general population.
Aim:
The purpose of this article is to provide a comprehensive summary of the etiology, symptoms, diagnosis and treatment of hereditary hemochromatosis with an emphasis on the importance of early detection and treatment of the disease.
Review methods:
A thorough analysis of several dozen research studies from recent years on hereditary hemochromatosis and its complications was conducted. Studies available in PUBMED were reviewed, the following keywords were used to search for sources: hemochromatosis; iron; hepcidin; phlebotomy; deferoxamine; therapeutic erythrocytapheresis.
Conclusion:
Hereditary hemochromatosis is a disease that in most patients runs a covert course. If unrecognized and untreated, it carries many life-threatening complications.
References
Molina CA, Ros NG, Tarancón RG, Varas LR, Flores VR, Álvarez SI. Hereditary hemochromatosis: An update vision of the laboratory diagnosis. J Trace Elem Med Biol. 2023 Jul;78:127194. doi: 10.1016/j.jtemb.2023.127194. Epub 2023 May 6. PMID: 37163822.
Crownover BK, Covey CJ. Hereditary hemochromatosis. Am Fam Physician. 2013 Feb 1;87(3):183-90. PMID: 23418762.
Kane SF, Roberts C, Paulus R. Hereditary Hemochromatosis: Rapid Evidence Review. Am Fam Physician. 2021 Sep 1;104(3):263-270. PMID: 34523883.
Hilton C, Sabaratnam R, Drakesmith H, Karpe F. Iron, glucose and fat metabolism and obesity: an intertwined relationship. Int J Obes (Lond). 2023 Jul;47(7):554-563. doi: 10.1038/s41366-023-01299-0. Epub 2023 Apr 7. PMID: 37029208; PMCID: PMC10299911.
Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment. Nutrients. 2021 Oct 22;13(11):3732. doi: 10.3390/nu13113732. PMID: 34835988; PMCID: PMC8619077.
Fowler C. Hereditary hemochromatosis: pathophysiology, diagnosis, and management. Crit Care Nurs Clin North Am. 2008 Jun;20(2):191-201, vi. doi: 10.1016/j.ccell.2008.01.003. PMID: 18424348.
Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020 Jan 31;105(2):260-272. doi: 10.3324/haematol.2019.232124. PMID: 31949017; PMCID: PMC7012465.
Nakanishi T, Kuragano T, Nanami M, Otaki Y, Nonoguchi H, Hasuike Y. Importance of ferritin for optimizing anemia therapy in chronic kidney disease. Am J Nephrol. 2010;32(5):439-46. doi: 10.1159/000320733. Epub 2010 Sep 30. PMID: 20881381.
Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017 Nov 1;29(9):401-409. doi: 10.1093/intimm/dxx031. PMID: 28541437; PMCID: PMC5890889.
Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. J Autoimmun. 2018 Sep;93:24-36. doi: 10.1016/j.jaut.2018.07.018. Epub 2018 Aug 1. PMID: 30077425.
Zhang N, Yu X, Xie J, Xu H. New Insights into the Role of Ferritin in Iron Homeostasis and Neurodegenerative Diseases. Mol Neurobiol. 2021 Jun;58(6):2812-2823. doi: 10.1007/s12035-020-02277-7. Epub 2021 Jan 28. PMID: 33507490.
Elsayed ME, Sharif MU, Stack AG. Transferrin Saturation: A Body Iron Biomarker. Adv Clin Chem. 2016;75:71-97. doi: 10.1016/bs.acc.2016.03.002. Epub 2016 May 6. PMID: 27346617.
Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler MU, Porto G. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood. 2022 May 19;139(20):3018-3029. doi: 10.1182/blood.2021011338. PMID: 34601591; PMCID: PMC11022970.
Joachim JH, Mehta KJ. Hepcidin in hepatocellular carcinoma. Br J Cancer. 2022 Jul;127(2):185-192. doi: 10.1038/s41416-022-01753-2. Epub 2022 Mar 9. PMID: 35264787; PMCID: PMC9296449.
Zhao Z. Iron and oxidizing species in oxidative stress and Alzheimer's disease. Aging Med (Milton). 2019 Jun 20;2(2):82-87. doi: 10.1002/agm2.12074. PMID: 31942516; PMCID: PMC6880687.
Kaur M, Lo SWS, Liu Y, Yip K. Hyperferritinemia: Important Differentials for the Rheumatologists. Cureus. 2024 Sep 3;16(9):e68588. doi: 10.7759/cureus.68588. PMID: 39371829; PMCID: PMC11450084.
Munankami S, Amin S, Shrestha M, Paudel R, Pokhrel A. Alcoholic Hepatitis Mimicking Iron Overload Disorders With Hyperferritinemia and Severely Elevated Transferrin Saturation: A Case Report. Cureus. 2023 Jul 11;15(7):e41727. doi: 10.7759/cureus.41727. PMID: 37575743; PMCID: PMC10415023.
Porto G, Brissot P, Swinkels DW, Zoller H, Kamarainen O, Patton S, Alonso I, Morris M, Keeney S. EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet. 2016 Apr;24(4):479-95. doi: 10.1038/ejhg.2015.128. Epub 2015 Jul 8. PMID: 26153218; PMCID: PMC4929861.
Murphree CR, Nguyen NN, Raghunathan V, Olson SR, DeLoughery T, Shatzel JJ. Diagnosis and management of hereditary haemochromatosis. Vox Sang. 2020 May;115(4):255-262. doi: 10.1111/vox.12896. Epub 2020 Feb 20. PMID: 32080859.
Piperno A, Bertola F, Bentivegna A. Juvenile Hemochromatosis. 2005 Feb 17 [updated 2020 Jan 9]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301349.
Cooray SD, Heerasing NM, Selkrig LA, Subramaniam VN, Hamblin PS, McDonald CJ, McLean CA, McNamara E, Leet AS, Roberts SK. Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report. J Med Case Rep. 2018 Jan 26;12(1):18. doi: 10.1186/s13256-017-1526-6. PMID: 29373985; PMCID: PMC5787235.
Roetto A, Totaro A, Cazzola M, Cicilano M, Bosio S, D'Ascola G, Carella M, Zelante L, Kelly AL, Cox TM, Gasparini P, Camaschella C. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet. 1999 May;64(5):1388-93. doi: 10.1086/302379. PMID: 10205270; PMCID: PMC1377875.
Adams P.C., Barton J.C., McLaren G.D., Acton R.T., Speechley M.I. i wsp.: Screening for iron overload: lessons from the hemochromatosis and iron overload screening (HEIRS) Study. Can J Gastroenterol 2009, 23, 769‑772.
Legros L, Bardou-Jacquet E, Latournerie M, Guillygomarc'h A, Turlin B, Le Lan C, Désille Y, Lainé F, Moirand R, Brissot P, Deugnier Y, Guyader D. Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis. Liver Int. 2015 Jun;35(6):1731-8. doi: 10.1111/liv.12762. Epub 2015 Feb 4. PMID: 25495562.
Durupt S, Durieu I, Nové-Josserand R, Bencharif L, Rousset H, Vital Durand D. L'hémochromatose génétique [Hereditary hemochromatosis]. Rev Med Interne. 2000 Nov;21(11):961-71. French. doi: 10.1016/s0248-8663(00)00252-6. PMID: 11109593.
Infanti L, Leitner G, Moe M, Pehlic V, Cattaneo M, Benkert P, Holbro A, Passweg J, Worel N, Buser A. Blood donation for iron removal in individuals with HFE mutations: study of efficacy and safety and short review on hemochromatosis and blood donation. Front Med (Lausanne). 2024 Mar 19;11:1362941. doi: 10.3389/fmed.2024.1362941. PMID: 38566922; PMCID: PMC10986032.
Walter K. What Is Hereditary Hemochromatosis? JAMA. 2022 Nov 8;328(18):1879. doi: 10.1001/jama.2022.19462. PMID: 36346414.
Little DR. Hemochromatosis: diagnosis and management. Am Fam Physician. 1996 Jun;53(8):2623-8, 2631-2. PMID: 8644575.
Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):819-837. doi: 10.1161/CIRCRESAHA.117.310982. PMID: 28912185.
Rapezzi C, Aimo A, Barison A, Emdin M, Porcari A, Linhart A, Keren A, Merlo M, Sinagra G. Restrictive cardiomyopathy: definition and diagnosis. Eur Heart J. 2022 Dec 1;43(45):4679-4693. doi: 10.1093/eurheartj/ehac543. PMID: 36269634; PMCID: PMC9712030.
Reichart D, Magnussen C, Zeller T, Blankenberg S. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes: A translational review of current literature. J Intern Med. 2019 Oct;286(4):362-372. doi: 10.1111/joim.12944. Epub 2019 Jul 29. PMID: 31132311.
Schultheiss HP, Fairweather D, Caforio ALP, Escher F, Hershberger RE, Lipshultz SE, Liu PP, Matsumori A, Mazzanti A, McMurray J, Priori SG. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019 May 9;5(1):32. doi: 10.1038/s41572-019-0084-1. PMID: 31073128; PMCID: PMC7096917.
Joshi PK, Patel SC, Shreya D, Zamora DI, Patel GS, Grossmann I, Rodriguez K, Soni M, Sange I. Hereditary Hemochromatosis: A Cardiac Perspective. Cureus. 2021 Nov 29;13(11):e20009. doi: 10.7759/cureus.20009. PMID: 34987900; PMCID: PMC8716004.
Hino K, Yanatori I, Hara Y, Nishina S. Iron and liver cancer: an inseparable connection. FEBS J. 2022 Dec;289(24):7810-7829. doi: 10.1111/febs.16208. Epub 2021 Oct 14. PMID: 34543507.
Kew MC. Hepatic iron overload and hepatocellular carcinoma. Liver Cancer. 2014 Mar;3(1):31-40. doi: 10.1159/000343856. PMID: 24804175; PMCID: PMC3995380.
Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am. 2005 Mar;89(2):391-409. doi: 10.1016/j.mcna.2004.08.005. PMID: 15656932.
Mehta N. Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management. Clin Liver Dis (Hoboken). 2021 Jun 4;17(5):332-336. doi: 10.1002/cld.1054. PMID: 34136137; PMCID: PMC8177830.
Sugawara Y, Hibi T. Surgical treatment of hepatocellular carcinoma. Biosci Trends. 2021 Jul 6;15(3):138-141. doi: 10.5582/bst.2021.01094. Epub 2021 Mar 19. PMID: 33746184.
Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020 Jun 10;5(1):87. doi: 10.1038/s41392-020-0187-x. PMID: 32532960; PMCID: PMC7292831.
McDermott JH, Walsh CH. Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab. 2005 Apr;90(4):2451-5. doi: 10.1210/jc.2004-0980. Epub 2005 Jan 18. PMID: 15657376.
Pelusi C, Gasparini DI, Bianchi N, Pasquali R. Endocrine dysfunction in hereditary hemochromatosis. J Endocrinol Invest. 2016 Aug;39(8):837-47. doi: 10.1007/s40618-016-0451-7. Epub 2016 Mar 7. PMID: 26951056.
El Osta R, Grandpre N, Monnin N, Hubert J, Koscinski I. Hypogonadotropic hypogonadism in men with hereditary hemochromatosis. Basic Clin Androl. 2017 Jul 8;27:13. doi: 10.1186/s12610-017-0057-8. PMID: 28694969; PMCID: PMC5501943.
Creighton Mitchell T, McClain DA. Diabetes and hemochromatosis. Curr Diab Rep. 2014;14(5):488. doi: 10.1007/s11892-014-0488-y. PMID: 24682660.
Barton JC, Acton RT. Diabetes in HFEHemochromatosis. J Diabetes Res. 2017;2017:9826930. doi: 10.1155/2017/9826930. Epub 2017 Feb 26. PMID: 28331855; PMCID: PMC5346371.
Feingold KR. Atypical Forms of Diabetes. 2022 Feb 24. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905351.
Jordan JM. Arthritis in hemochromatosis or iron storage disease. Curr Opin Rheumatol. 2004 Jan;16(1):62-6. doi: 10.1097/00002281-200401000-00012. PMID: 14673391.
Husar-Memmer E, Stadlmayr A, Datz C, Zwerina J. HFE-related hemochromatosis: an update for the rheumatologist. Curr Rheumatol Rep. 2014 Jan;16(1):393. doi: 10.1007/s11926-013-0393-4. PMID: 24264720.
Andersson L, Powell LW, Ramm LE, Ramm GA, Olynyk JK. Arthritis Prediction of Advanced Hepatic Fibrosis in HFE Hemochromatosis. Mayo Clin Proc. 2022 Sep;97(9):1649-1655. doi: 10.1016/j.mayocp.2022.02.017. Epub 2022 Apr 12. PMID: 35422339.
Barton JC, Parker CJ. HFE-Related Hemochromatosis. 2000 Apr 3 [updated 2024 Apr 11]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301613.
Girelli D, Marchi G, Busti F. Diagnosis and management of hereditary hemochromatosis: lifestyle modification, phlebotomy, and blood donation. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):434-442. doi: 10.1182/hematology.2024000568. PMID: 39644049; PMCID: PMC11665571.
Poullin P, Lefèvre P. L'érythraphérèse thérapeutique : technique et applications cliniques [Therapeutic erythrocytapheresis: technical aspects and clinical applications]. Rev Med Interne. 2008 Apr;29(4):290-6. French. doi: 10.1016/j.revmed.2007.10.406. Epub 2007 Nov 20. PMID: 18280010.
Valbonesi M, Bruni R. Clinical application of therapeutic erythrocytapheresis (TEA). Transfus Sci. 2000 Jun;22(3):183-94. doi: 10.1016/s0955-3886(00)00042-4. PMID: 10831921.
Kang Y, Chen XJ, Yu CP, You GY, Zhang Q. Severe Myocardial Dysfunction Reversed by Iron-Chelation Therapy in an Asian Patient with Hereditary Hemochromatosis. Am J Med Sci. 2016 May;351(5):546-8. doi: 10.1016/j.amjms.2016.02.038. Epub 2016 Mar 2. PMID: 27140717.
Hruby M, Martínez IIS, Stephan H, Pouckova P, Benes J, Stepanek P. Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers. Polymers (Basel). 2021 Nov 17;13(22):3969. doi: 10.3390/polym13223969. PMID: 34833268; PMCID: PMC8618197.
Ruivard M, Lobbes H. Diagnostic et traitement d’une surcharge en fer [Diagnosis and treatment of iron overload]. Rev Med Interne. 2023 Dec;44(12):656-661. French. doi: 10.1016/j.revmed.2023.07.002. Epub 2023 Jul 26. PMID: 37507250.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Dominika Prystacka-Szar, Natalia Rulewska, Filip Grabowski, Jakub Siemko, Dagmara Neska , Justyna Stadler-Szajda, Adrianna Czyżnikiewicz, Wenancjusz Stołowski, Magdalena Bujak, Magdalena Waśniowska

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 36
Number of citations: 0